Verified peer comparison

BDX vs BSX

Becton, Dickinson and Company compared with Boston Scientific Corporation. This page compares both source-verified company profiles and does not introduce an unverified price target.

BDX

Becton, Dickinson and Company

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

BSX

Boston Scientific Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

BDX: Health Care Equipment

BSX: Health Care Equipment

Upside lens

BDX: A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. New pharmacy automation, microbiology and interventional products can improve mix and customer workflows. A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

BSX: FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications. A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

Risk lens

BDX: Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits. Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs. Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

BSX: Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms. Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio. Large rivals and new technologies can pressure pricing, physician loyalty and market share.

Verified sources

BD Reports Second Quarter Fiscal 2026 Financial ResultsBecton, Dickinson and Company · earningsVerified